Ambipar confirmed on November 16—its regulatory deadline—that its third-quarter 2026 financial report would not be released. With this delay, AMBP3 stock has accumulated five consecutive unfiled financial reports with no new release date promised, while its judicial reorganization plan awaits an STJ decision before creditors can even vote on it.
AMBP3 Stock News Today: What Happened to the 3Q26 Financial Report?
Ambipar failed to deliver its third-quarter 2026 financial report by the November 16 deadline. In a statement to the market, the company attributed the delay to its judicial reorganization process, which "impacted the completion of the auditing and preparation of financial and accounting information." No new date was provided.
For investors following AMBP3, the delay is not a surprise—but it marks the longest streak yet. The company has not published any financial results since before its judicial reorganization filing on October 20, 2025. The 3Q26 report is the fifth document to be delayed:
Why Five Pending Financial Reports Mean More Than Just Bureaucratic Trouble
The consecutive delay of reports removes the only concrete tool investors have to evaluate whether the situation has improved or worsened since October 2025. Without audited figures, any thesis—whether recovery or liquidation—is pure speculation about what may be inside these documents.
Brazil's securities regulator, the CVM, has already gone to court to access confidential documents from the judicial reorganization process. The target of this regulatory initiative is a specific inconsistency: in June 2025, Ambipar reported having R$ 4.7 billion in cash. Four months later, in October, the company claimed it was unable to honor its obligations and filed for court protection. The CVM described this gap as something that "reinforces the need for information on actual cash availability"—a formal way of saying that the market regulator also does not know where the billions in cash went.
The lack of financial reports also has a direct impact on the stock. AMBP3 was removed from all B3 indexes due to governance issues after the process began. Trading at R$ 0.13 on November 16—an estimated drop of approximately 96% since the reorganization filing—the market is pricing in an extreme risk of loss rather than a valuation discount. This week, which marked the close of the 3Q26 earnings season, other companies published their results, including negative figures such as PDGR3's R$ 64.5 million loss in 3Q26. A bad result at least gives investors measurable information. Silence delivers nothing.
The Restructuring Plan: RSA Signed, Creditor Assembly Blocked at the STJ
In July 2026, Ambipar announced concrete progress in the process. It signed a Restructuring Support Agreement (RSA) with creditors holding a majority stake in its Green Notes—the external bonds at the core of the crisis. Under the agreement, $1.043 billion in existing notes would be restructured into $925 million in new secured notes, with two payments of $25 million each. Itaú BBA International also agreed to extend part of its overdue debt. The company thus signaled that it has the support of major foreign creditors for the plan.
The problem is that the plan needed to be submitted to a General Creditors' Meeting for a vote and then approved by the court. The meeting was scheduled for September 1—but the STJ suspended the gathering via an injunction even before it began.
Justice Raul Araújo, the reporting judge at the STJ, granted an injunction requested by a group of creditors—including the Ativos Especiais III fund (from Vinci, which acquired R$ 663 million in debt from Santander), Sumitomo, Banco ABC, and asset manager Jive—who challenged the venue of the proceeding. Their argument: Ambipar's "principal establishment" is located in São Paulo, not Rio de Janeiro, where the case is being handled. The justice rejected a request from the company to resume the vote, and the meeting remains suspended while the court resolves the dispute over the appropriate jurisdiction.
On September 28, 2026, the U.S. bankruptcy court recognized the Brazilian judicial reorganization as a "foreign main proceeding" under Chapter 15—a victory that consolidates Brazil as the responsible jurisdiction and prevents foreign creditors from seizing assets in the U.S. while the process unfolds locally. However, the U.S. ruling neither approves nor advances the plan in Brazil: the creditors' meeting remains suspended, and the RSA signed in July does not bind local debenture holders and Brazilian banks, who may negotiate different terms.
Two Possible Paths From Here
The court rules in favor of Rio de Janeiro as the competent venue. The creditors' meeting is called within weeks; the RSA already signed with the Green Notes creditors provides a concrete basis for majority approval. The approved plan paves the way for operational restructuring and removes the formal obstacle preventing the publication of overdue financial reports.
The court orders the case transferred to São Paulo. The entire process starts over in a new court: new deadlines, new judicial administration, and the risk that the stay period—the protection preventing creditors from enforcing claims—will be renegotiated. The RSA may require renegotiation. Shareholders go longer without information and without any prospect of a plan vote, while the company burns operational cash.
Investors holding AMBP3 have gone more than a year without the most basic data for any evaluation: the financial reports. The R$ 0.13 share price may seem negligible, but penny stocks of companies in judicial reorganization are not cheap—they reflect extreme uncertainty about the final value shareholders will receive after restructuring, which frequently includes significant dilution or debt-to-equity conversion. The central question—does the reorganization plan reserve any real value for common shareholders, or does the recovery primarily serve creditors?—depends on the terms of the plan, which has not yet been voted on. Meanwhile, investors looking to buy based on a low price perception face the additional risk that, without audited financial reports for over a year, there is no way to know whether R$ 0.13 represents a discount or a fair pricing of total loss risk.
What to Monitor in the Coming Months
STJ decision on the competent venue (Rio de Janeiro vs. São Paulo) — no set deadline; Justice Raul Araújo can rule at any time. This is the catalyst for the entire schedule: until the dispute is resolved, no creditors' meeting can take place, the plan cannot advance, and the stay period remains uncertain. Monitor Ambipar's filings on the CVM's RAD system.
Publication of accumulated financial reports — the company states it is "making every effort" to release the five pending reports, without a timeline. The first published result will change the baseline for any evaluation and may reveal the fate of the cash balance that stood at R$ 4.7 billion in June 2025. Watch for market filings on the CVM RAD system, which is the company's only active information channel at the moment.
Calling of the creditors' meeting and voting on the reorganization plan — this will only occur after the STJ defines the venue. The RSA signed with Green Notes creditors (who hold a majority of the $1.043 billion in external debt) provides a basis for approval by that group, but does not bind local debenture holders and Brazilian banks. Majority approval plus court homologation is the path to an orderly restructuring; rejection would clear the way for bankruptcy proceedings.